LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal ...
manilatimes1mon
LB Pharmaceuticals Announces Key Executive Appointments to Support Growth and Late-Stage Development of LB-102
Gad Soffer Joins as Chief Business Officer and Richard Silva, Ph.D., as Senior Vice President of Technical Operations NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc., a ...
Yahoo Finance21d
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
PASADENA, CALIF., March 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage ...
The Globe and Mail21d
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
LIXT and LIXTW), a clinical-stage pharmaceutical company, today announced online publication of new pre-clinical data in BioXriv and International Journal of Pharmaceutics demonstrating how the ...